Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Sabra Health Care REIT, Inc.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-73.8% vs price
Base Case (Median)
-57.0% vs price
Bull Case (75th pct.)
-19.7% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $39.48 | 106.4% | High (40%) |
| PE Comparable | $3.98 | -79.2% | Medium (25%) |
| Growth Trajectory DCF | $1.48 | -92.3% | Medium (20%) |
| Graham Number | $8.09 | -57.7% | Low (10%) |
| EV/EBITDA | $8.34 | -56.4% | Medium (20%) |
| EV/FCF | $17.69 | -7.5% | Medium (20%) |
Based on 6 out of 7 methods, SBRA appears overvalued at the current price of $19.13. The base case fair value of $8.22 implies 57.0% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.